
    
      In this proposal, the investigators aim to explore the clinical subtypes and biological
      markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD. By stratifying the
      subjects with (versus without) remission and treatment response, the biological markers are
      expected to have important prediction effects in future clinical practice.
    
  